Fri, 29 Jan 2021
Source: reuters.com
South Africa’s mid-stage trial of U.S.-based biotech company Novavax Inc’s COVID-19 vaccine has shown it to be 60% effective for non-HIV individuals, the principal investigator of the study said late on Thursday.
Shabir Madhi, a professor of vaccinology at the University of the Witwatersrand leading the clinical study for Novavax COVID-19 vaccine in South Africa, said the results were good and showed the vaccine is highly effective towards immunization against the coronavirus.
“The results are far superior than any other vaccine against the new variant,” Madhi said.
Source: reuters.com
Related Articles:
- Expanding Africa’s vaccine production capacity key – Noguchi Director
- Dengue fever epidemic declared in Burkina Faso
- Frontiers earned over $87m while government got under $7m from COVID testing at KIA – Report
- I donated PPE worth over $1 million during COVID-19 pandemic – Ken Agyapong
- Ablakwa releases ‘inaccessible details’ of contract awarded to Frontiers for COVID test at the airport
- Read all related articles